Imagine something as simple as sitting for a long period makes you tired. Or not being able to visit family because a long drive could result in a car accident. For the hundreds of thousands of sufferers of narcolepsy, these are just some of the daily struggles they must endure.
In addition to daytime sleepiness, symptoms can include hallucinations, sleep disruption, sleep paralysis, and cataplexy, where all the muscles suddenly lose their tension and stiffness, leading to the loss of voluntary muscle control. These frustrating and potentially dangerous symptoms ultimately have a devastating impact on people’s lives at school, work, and as everyday tasks are dramatically disrupted.
Harmony Biosciences is a commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with narcolepsy and other rare neurological disorders. In 2019, Harmony received FDA approval for its first commercial product, WAKIX.
The tablet is a first-in-class molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Subsequently, in 2020, WAKIX was approved by the FDA for the treatment of cataplexy. WAKIX is the first-and-only approved product for patients with narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration.
In addition to continuing to optimize the performance of WAKIX across its currently approved indications, Harmony is focused on expanding the clinical use of WAKIX across pediatric applications, broader use in neurological disorders that may be mediated by the H3 receptor, whilst also looking to acquire new assets to expand the company’s portfolio. Harmony Biosciences Holdings, Inc.Harmony Biosciences Holdings, Inc.